Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia: Molecular Therapy - Oncolytics
CD33 Antikörper (P67.6) | SCBT - Santa Cruz Biotechnology
CeD defined by the identification of a novel bio-profile marker CD33... | Download Scientific Diagram
JCI - SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection
CD33 Monoclonal Antibody (9A11-CD33), PE, eBioscience™, Invitrogen™ 25 μg; PE CD33 Monoclonal Antibody (9A11-CD33), PE, eBioscience™, Invitrogen™ | Fisher Scientific
CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing | Journal of Neuroscience
Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination - eBioMedicine
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies | PNAS
Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia - ScienceDirect
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia | Haematologica
Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia - ScienceDirect
Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates: Molecular Therapy Methods & Clinical Development
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies | PNAS
CD33 - an overview | ScienceDirect Topics
CD33 - Biocare Medical
Frontiers | Neutrophils: Need for Standardized Nomenclature
CD33 antigen expression on human polyclonal T cells activated by... | Download Scientific Diagram
CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer | Cell Death & Disease
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia | PLOS ONE
![PDF] Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d34a0648c6b7aec184e76fd71834ebaf973d2f1b/4-Figure2-1.png "PDF] Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. | Semantic Scholar")
PDF] Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. | Semantic Scholar
Frontiers | Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia | Journal for ImmunoTherapy of Cancer
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy | Leukemia
Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia | Scientific Reports
![PDF] Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d34a0648c6b7aec184e76fd71834ebaf973d2f1b/4-Table1-1.png "PDF] Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. | Semantic Scholar")
PDF] Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. | Semantic Scholar
CD33 Antikörper APC (ABIN775711)
